Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VC005 tolerance and PK/PD in healthy subjects
NCT05354752Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing VC005 Tablets with Placebo (2 arms). Primary endpoints: Peak Plasma Concentration at Day 2, Area under the plasma concentration versus time curve at Day 2 and 3 more. Started Jun 2022; status: completed.
02
Drugs
VC-005
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05354752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354752.